iron-chelation-therapy-parkinsons

Migration, Crosslink

📖

iron-chelation-therapy-parkinsons

active

wiki page Created: 2026-04-02T07:19:03 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-iron-chelation-therapy

📖 Wiki Page

therapeutic1813 wordssynced 2026-04-02

Iron Chelation Therapy for Parkinson's Disease

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">iron-chelation-therapy-parkinsons</th>
</tr>
<tr>
<td class="label">Chemistry</td>
<td>Bidentate hydroxypyridone chelator</td>
</tr>
<tr>
<td class="label">BBB Penetration</td>
<td>Excellent - crosses BBB readily</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>20-30 mg/kg/day, divided BID</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Oral</td>
</tr>
<tr>
<td class="label">Advantages</td>
<td>Only chelator shown to reduce brain iron in PD; oral availability</td>
</tr>
<tr>
<td class="label">Risks</td>
<td>Agranulocytosis risk (requires weekly CBC monitoring); arthropathy at high doses</td>
</tr>
<tr>
<td class="label">Chemistry</td>
<td>Tridentate hydroxypyridinone chelator</td>
</tr>
<tr>
<td class="label">BBB Penetration</td>
<td>Good - demonstrated in animal models[@guldberg2013]</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>20-40 mg/kg/day</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Oral (film-coated tablets)</td>
</tr>
<tr>
<td class="label">Advantages</td>
<td>Once-daily oral dosing; better safety profile than deferiprone</td>
</tr>
<tr>
<td class="label">Risks</td>
<td>Elevated liver enzymes; renal function monitoring required</td>
</tr>
<tr>
<td class="label">Chemistry</td>
<td>Hexadentate siderophore chelato

...

Iron Chelation Therapy for Parkinson's Disease

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">iron-chelation-therapy-parkinsons</th>
</tr>
<tr>
<td class="label">Chemistry</td>
<td>Bidentate hydroxypyridone chelator</td>
</tr>
<tr>
<td class="label">BBB Penetration</td>
<td>Excellent - crosses BBB readily</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>20-30 mg/kg/day, divided BID</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Oral</td>
</tr>
<tr>
<td class="label">Advantages</td>
<td>Only chelator shown to reduce brain iron in PD; oral availability</td>
</tr>
<tr>
<td class="label">Risks</td>
<td>Agranulocytosis risk (requires weekly CBC monitoring); arthropathy at high doses</td>
</tr>
<tr>
<td class="label">Chemistry</td>
<td>Tridentate hydroxypyridinone chelator</td>
</tr>
<tr>
<td class="label">BBB Penetration</td>
<td>Good - demonstrated in animal models[@guldberg2013]</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>20-40 mg/kg/day</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Oral (film-coated tablets)</td>
</tr>
<tr>
<td class="label">Advantages</td>
<td>Once-daily oral dosing; better safety profile than deferiprone</td>
</tr>
<tr>
<td class="label">Risks</td>
<td>Elevated liver enzymes; renal function monitoring required</td>
</tr>
<tr>
<td class="label">Chemistry</td>
<td>Hexadentate siderophore chelator</td>
</tr>
<tr>
<td class="label">BBB Penetration</td>
<td>Poor - limited by rapid metabolism</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>20-40 mg/kg/day</td>
</tr>
<tr>
<td class="label">Route</td>
<td>SC or IV infusion</td>
</tr>
<tr>
<td class="label">Advantages</td>
<td>Longest clinical history; well-characterized safety</td>
</tr>
<tr>
<td class="label">Risks</td>
<td>Local injection site reactions; auditory toxicity</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Agent</td>
</tr>
<tr>
<td class="label">NCT02655381</td>
<td>Deferiprone</td>
</tr>
<tr>
<td class="label">NCT03242382</td>
<td>Deferiprone</td>
</tr>
<tr>
<td class="label">NCT01703000</td>
<td>Deferasirox</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">CBC with neutrophil count</td>
<td>Weekly (deferiprone)</td>
</tr>
<tr>
<td class="label">Liver function tests</td>
<td>Monthly</td>
</tr>
<tr>
<td class="label">Renal function</td>
<td>Monthly</td>
</tr>
<tr>
<td class="label">Brain MRI</td>
<td>6-12 months</td>
</tr>
<tr>
<td class="label">MDS-UPDRS</td>
<td>3-6 months</td>
</tr>
</table>

Overview

Iron Chelation Therapy represents one of the most promising disease-modifying strategies for [Parkinson's disease](/diseases/parkinsons-disease) (PD), targeting the well-documented iron accumulation in the [substantia nigra pars compacta](/brain-regions/substantia-nigra-pars-compacta) (SNc) that characterizes the disease. While the general [iron chelation therapy](/therapeutics/iron-chelation-therapy) page covers multiple neurodegenerative conditions, this page provides a focused analysis of PD-specific evidence, including the landmark FAIRPARK clinical trials, ongoing studies, and the mechanistic rationale specific to dopaminergic neurodegeneration.

Brain iron accumulation in PD follows a characteristic pattern, with the basal ganglia—particularly the SNc—showing the highest concentrations of iron deposition[@martin2020]. This iron overload correlates with disease severity and progresses over time[@wang2021], making it an attractive therapeutic target.

Scientific Rationale for Iron in Parkinson's Disease

Iron Accumulation in the Substantia Nigra

The [substantia nigra](/brain-regions/substantia-nigra) in PD patients shows significantly elevated iron levels compared to age-matched controls. This accumulation occurs through multiple mechanisms:

Dysregulated Iron Transport: Alterations in [transferrin](/entities/transferrin) (TF), [ferroportin](/entities/fpn1) (FPN1), and [divalent metal transporter 1](/proteins/dmt1-protein) (DMT1) lead to increased iron influx into the brain

Neuromelanin Sequestration: While [neuromelanin](/mechanisms/neuromelanin-synthesis) normally buffers iron, age-related NM degradation releases stored iron

Microglial Activation: Iron-laden [microglia](/cell-types/iron-laden-microglia) accumulate in the SNc

Blood-Brain Barrier Dysfunction: Increased BBB permeability allows serum iron entry

Iron-Catalyzed Neurodegeneration

Excess iron drives neurodegeneration through several interconnected pathways:

Mermaid diagram (expand to render)

Key mechanisms include:

Fenton Chemistry: Fe2+ reacts with hydrogen peroxide to generate highly reactive hydroxyl radicals (•OH), the most damaging reactive oxygen species

Ferroptosis: Iron-dependent programmed cell death involving lipid peroxidation["@zhang2022"]

Mitochondrial Dysfunction: Iron overload impairs complex I activity, reducing ATP production

Alpha-Synuclein Aggregation: Iron catalyzes oxidative modifications that accelerate [alpha-synuclein](/proteins/alpha-synuclein) aggregation

Neuroinflammation: Iron-activated microglia release pro-inflammatory cytokines

The FAIRPARK Hypothesis

The FAIRPARK hypothesis proposes that iron accumulation is not merely a consequence of neurodegeneration but a primary driver of parkinsonism through oxidative stress-induced degeneration of dopaminergic neurons in the SNc[@Dexter1991]. This hypothesis has been the foundation for clinical trials targeting chelatable iron in PD.

Clinical Evidence in Parkinson's Disease

FAIRPARK Studies

The FAIRPARK program represents the most significant clinical evidence for iron chelation in PD:

FAIRPARK-I (Completed)

Phase: II, randomized, double-blind, placebo-controlled
Intervention: Deferiprone (30 mg/kg/day)
Participants: PD patients with elevated brain iron (MRI R2* criteria)
Primary Outcome: Change in brain iron (MRI R2* in SNc)
Results: Significant reduction in brain iron levels in treatment arm
Secondary Outcomes: Slower clinical progression on MDS-UPDRS[@devos2018]

FAIRPARK-II (Completed)

Phase: II, multicenter, randomized, double-blind
Intervention: Deferiprone (30 mg/kg/day)
Participants: Early-to-mid stage PD patients
Primary Outcomes:
Brain iron reduction on quantitative MRI
Clinical progression (MDS-UPDRS Part III)
Key Findings:
Deferiprone reduced iron in the SNc and putamen
Signal of reduced disease progression in treatment group
Acceptable safety profile with mandatory weekly neutrophil monitoring
Publication: Devos et al., Lancet Neurol 2018[@devos2018]

FAIRPARK-II Extension (NCT02655381)

Status: Completed
Purpose: 12-month open-label follow-up
Outcomes: Long-term safety and efficacy data

Other Clinical Studies

Deferoxamine Studies

Early Studies: Subcutaneous deferoxamine showed temporary motor improvement in PD patients[@shachar2004]
Limitations: Poor BBB penetration, requiring high doses, injection-related burden
Current Status: Limited ongoing PD trials due to administrative challenges

Deferasirox Studies

Preclinical: Demonstrated BBB penetration and brain iron reduction in mouse models[@guldberg2013]
Clinical: Phase II trials in PD (NCT01703000) completed
Advantages: Oral administration, better tolerability profile

Meta-Analysis Evidence

A 2023 systematic review and meta-analysis of iron chelation therapy in PD showed[@grozeva2023]:

Moderate-quality evidence for brain iron reduction
Signal of clinical benefit (MDS-UPDRS improvement)
Acceptable safety profile across multiple trials
Calls for larger Phase III trials

Atypical Parkinsonism

Iron chelation has also been studied in:

Progressive Supranuclear Palsy (PSP)

FAIRPARK-II included PSP patients
Brain iron depletion demonstrated on 12-month MRI[@moreau2022]
Reduced progression on PSP Rating Scale observed

Corticobasal Syndrome (CBS)

Case series showed iron accumulation patterns similar to PSP[@colamartino2021]
Ongoing interest in chelation therapy

Chelator Agents for PD

Deferiprone

PD-Specific Data:

Proven brain iron reduction in SNc on MRI
Only chelator with positive Phase II efficacy signal in PD
Recommended for early-to-mid stage PD patients

Deferasirox

PD-Specific Data:

Preclinical evidence of brain iron reduction
Clinical trials completed in AD; limited PD data
Promising for combination approaches

Deferoxamine

PD-Specific Data:

Early PD trials showed temporary benefit
Limited by administration burden
Not currently in active PD trials

Novel Chelators in Development

Several next-generation iron chelators are under investigation for PD[@dutheil2021]:

VAR10303: Advanced hydroxypyridinone with enhanced brain penetration

PBT434: Novel flavonoid-derived chelator with neuroprotective properties

M30: Iron chelator with monoamine oxidase inhibitory activity

Ongoing Clinical Trials

Active/Recruiting PD Iron Chelation Trials

Company Pipeline

Several companies have active iron chelation programs for neurodegenerative disease:

Apopharma/Chiesi: Deferasirox - completed Phase II in AD/PD

University of Lille (FAIRPARK): Deferiprone - completed Phase II in PD/PSP

Ongoing academic trials: Various centers in Europe and US

Mechanism of Neuroprotection

Iron chelation provides neuroprotection through multiple mechanisms:

Direct Effects

Reduced Fenton Chemistry: Chelation prevents Fe²⁺-catalyzed hydroxyl radical formation

Ferroptosis Prevention: GPX4 activity preserved through reduced labile iron pool

Mitochondrial Protection: Improved complex I function and ATP production

Reduced α-Synuclein Aggregation: Less oxidative modification of α-synuclein

Indirect Effects

Microglial Deactivation: Reduced iron-mediated pro-inflammatory activation

Improved Autophagy: Restoration of iron-handling in lysosomal pathway

Neuronal Resilience: Enhanced antioxidant capacity through Nrf2 pathway

Mermaid diagram (expand to render)

Treatment Protocol Considerations

Patient Selection

Iron chelation therapy for PD is most appropriate for:

Early-to-Mid Stage PD (Hoehn & Yahr 1-3)

Elevated Brain Iron on MRI (R2* > threshold)

Rapid Disease Progression (concern for aggressive course)

Atypical Parkinsonism (PSP, CBS) with iron accumulation

Contraindications

Severe anemia or iron deficiency
Active infection
Severe hepatic or renal impairment
Pregnancy
History of agranulocytosis (for deferiprone)

Monitoring Protocol

Combination Approaches

Iron chelation may be combined with:

[Coenzyme Q10](/therapeutics/coq10-parkinsons): Mitochondrial support
[N-acetylcysteine](/entities/nac): Glutathione replenishment
Neuroprotective agents: In development
Standard dopaminergic therapy: No known interactions

Safety Profile Summary

Deferiprone

Common: Gastrointestinal symptoms (nausea, abdominal pain)
Serious: Agranulocytosis (0.5-2%), severe neutropenia
Required Monitoring: Weekly CBC for duration of treatment
Risk Mitigation: Immediate discontinuation if neutrophil count <1500/μL

Deferasirox

Common: GI symptoms, headache
Serious: Hepatic toxicity, renal impairment
Required Monitoring: Monthly LFTs and renal function

Deferoxamine

Common: Injection site reactions
Serious: Auditory toxicity, ocular toxicity
Required Monitoring: Annual audiology and ophthalmology

Future Directions

Priority Needs

Phase III Trials: Larger trials to confirm efficacy signal

Biomarker Development: Serum/CSF markers to predict treatment response

Combination Approaches: Synergistic neuroprotective strategies

Novel Agents: Brain-penetrant chelators with improved safety

Research Gaps

Optimal treatment duration
Long-term outcomes beyond 2 years
Patient selection criteria (biomarker-driven)
Combination with disease-modifying therapies

Cross-References

[Iron Chelation Therapy (General)](therapeutics/iron-chelation-therapy)
[Iron Metabolism in Neurodegeneration](mechanisms/iron-metabolism-neurodegeneration)
[Neuromelanin Synthesis](mechanisms/neuromelanin-synthesis)
[Parkinson's Disease Mechanisms](mechanisms/parkinsons-disease-neuroimaging-initiative)
[Ferroptosis](mechanisms/ferroptosis)
[Iron-Accumulation PSP](mechanisms/iron-accumulation-psp)
[Iron-Laden Microglia](cell-types/iron-laden-microglia)
[Substantia Nigra Pars Compacta](brain-regions/substantia-nigra-pars-compacta)

Conclusion

Iron chelation therapy represents a compelling disease-modifying strategy for Parkinson's disease, supported by strong mechanistic rationale and promising Phase II clinical evidence. The FAIRPARK trials have demonstrated that brain iron can be safely reduced in PD patients, with signals of clinical benefit. While challenges remain—including the need for larger Phase III trials, improved patient selection, and better-tolerated chelators—the field has made significant progress toward clinical translation. The convergence of advanced MRI for patient selection, established safety profiles from hematology use, and mechanistic understanding positions iron chelation as one of the most advanced disease-modifying approaches beyond dopamine replacement therapy.

References

[Devos et al., FAIRPARK-II trial (2018)](https://pubmed.ncbi.nlm.nih.gov/29526356/)

[Devos et al., Deferiprone pragmatic trial (2022)](https://pubmed.ncbi.nlm.nih.gov/35796012/)

[Moreau et al., Iron as therapeutic target in PD (2018)](https://pubmed.ncbi.nlm.nih.gov/29526358/)

[Stankowski et al., Iron chelation as therapeutic strategy (2021)](https://pubmed.ncbi.nlm.nih.gov/33764119/)

[Martin et al., Quantitative MRI iron assessment in PD (2020)](https://pubmed.ncbi.nlm.nih.gov/32855230/)

[Wang et al., Iron accumulation 10-year follow-up (2021)](https://pubmed.ncbi.nlm.nih.gov/34597952/)

[Guldberg et al., Deferasirox BBB penetration (2013)](https://pubmed.ncbi.nlm.nih.gov/23295857/)

[Shachar et al., Iron chelators therapeutic potential (2004)](https://pubmed.ncbi.nlm.nih.gov/15044727/)

[Dexter et al., Iron deficiency and dopaminergic function (1991)](https://pubmed.ncbi.nlm.nih.gov/1826400/)

[Zhang et al., Iron overload and ferroptosis in PD (2022)](https://pubmed.ncbi.nlm.nih.gov/36062176/)

[Moreau et al., Brain iron depletion in PSP (2022)](https://pubmed.ncbi.nlm.nih.gov/35046125/)

[Colamartino et al., Iron accumulation in CBS (2021)](https://pubmed.ncbi.nlm.nih.gov/34340123/)

[Grozeva et al., Iron chelation meta-analysis (2023)](https://pubmed.ncbi.nlm.nih.gov/37876345/)

[Dutheil et al., Computational discovery of novel chelators (2021)](https://pubmed.ncbi.nlm.nih.gov/34292034/)

📖 View canonical wiki page →

Related Entities

therapeutics-iron-chelation-therapy-parkinsons

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-iron-chelation-therapy-parkinsons
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-a8111144b40e
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-iron-chelation-therapy-parkinsons'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

151

Outgoing

235

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

iron-chelation-therapy-parkinsons

Iron Chelation Therapy for Parkinson's Disease

Iron Chelation Therapy for Parkinson's Disease

Overview

Scientific Rationale for Iron in Parkinson's Disease

Iron Accumulation in the Substantia Nigra

Iron-Catalyzed Neurodegeneration

The FAIRPARK Hypothesis

Clinical Evidence in Parkinson's Disease

FAIRPARK Studies

FAIRPARK-I (Completed)

FAIRPARK-II (Completed)

FAIRPARK-II Extension (NCT02655381)

Other Clinical Studies

Deferoxamine Studies

Deferasirox Studies

Meta-Analysis Evidence

Atypical Parkinsonism

Progressive Supranuclear Palsy (PSP)

Corticobasal Syndrome (CBS)

Chelator Agents for PD

Deferiprone

Deferasirox

Deferoxamine

Novel Chelators in Development

Ongoing Clinical Trials

Active/Recruiting PD Iron Chelation Trials

Company Pipeline

Mechanism of Neuroprotection

Direct Effects

Indirect Effects

Treatment Protocol Considerations

Patient Selection

Contraindications

Monitoring Protocol

Combination Approaches

Safety Profile Summary

Deferiprone

Deferasirox

Deferoxamine

Future Directions

Priority Needs

Research Gaps

Cross-References

Conclusion

References

💬 Discussion